Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of an Optimized Dual GLP-1/GIP Receptor Agonist (BGM0504) in Healthy Subjects-A Phase Ia, Randomized, Double-Blind, Placebo-Controlled, Ascending Dose Study

被引：0
|
作者：
Yuan, Jiandong
Huang, Yangqing
Ding, Haifeng
Jiang, Xiaohui
机构：
来源：
DIABETES | 2024年 / 73卷
关键词：
D O I：
10.2337/db24-849-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
849-P
引用
收藏
页数：2
相关论文
共 50 条
  • [21] First-in-human safety, tolerability, and pharmacokinetics of ammoxetine in healthy subjects: a randomized, double-blind, placebo-controlled phase I study
    Shen, Qi
    Hu, Chao
    Miao, Jia
    Chen, Junxia
    Peng, Yueying
    Pan, Tingting
    He, Xiaolin
    Yuan, Jing
    Ni, Shaonan
    Wang, Yongsheng
    Luo, Zhu
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2021, 159
  • [22] Safety, tolerability and pharmacokinetics of WXFL10203614 in healthy Chinese subjects: A randomized, double-blind, placebo-controlled phase I study
    Huang, Kai
    Ding, Ying
    Que, Linling
    Chu, Nannan
    Shi, Yunfei
    Qian, Zhenzhong
    Qin, Wei
    Chen, Yuanxin
    Gu, Xianghong
    Wang, Jiakun
    Zhang, Zhiwei
    Xu, Jianguo
    He, Qing
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [23] A randomized, double-blinded, placebo-controlled single ascending dose study to assess safety, tolerability, immunogenicity, and pharmacokinetics of a novel long-acting GLP-1/GIP/glucagon triple agonist (hm15211) in healthy obese subjects
    Choi, JaeDuk
    Kim, Youngmin
    Eun, Kahee
    Morrow, Linda
    Hompesch, Marcus
    Baek, Seungjae
    JOURNAL OF HEPATOLOGY, 2020, 73 : S455 - S456
  • [24] A Randomized, Double-Blind, Placebo-Controlled, Single-Centre, Single Ascending Dose And Multiple Ascending Dose Study Of The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Molgramostim (rhgm-Csf) Administered By Inhalation To Healthy Adult Subjects
    Tarnow, I.
    Nymark, K.
    Vinge, M.
    Nielsen, K. A.
    Ganslandt, C.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [25] A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects
    Lesley Taylor
    Barry Gidal
    Graham Blakey
    Bola Tayo
    Gilmour Morrison
    CNS Drugs, 2018, 32 : 1053 - 1067
  • [26] A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects
    Taylor, Lesley
    Gidal, Barry
    Blakey, Graham
    Tayo, Bola
    Morrison, Gilmour
    CNS DRUGS, 2018, 32 (11) : 1053 - 1067
  • [27] Safety, Pharmacokinetics, and Pharmacodynamics of the TLR4 Agonist GSK1795091 in Healthy Individuals: Results from a Randomized, Double-blind, Placebo-controlled, Ascending Dose Study
    Hug, Bruce A.
    Matheny, Christopher J.
    Burns, Olivia
    Struemper, Herbert
    Wang, Xiaowei
    Washburn, Michael L.
    CLINICAL THERAPEUTICS, 2020, 42 (08) : 1519 - +
  • [28] Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of the Novel Dual GIP/GLP-1 Agonist (RG7697) after Single Subcutaneous Administration in Healthy Subjects
    Portron, Agnes
    Jadidi, Shirin
    Sarkar, Neena
    Dimarchi, Richard
    Schmitt, Christophe
    DIABETES, 2017, 66 : A624 - A624
  • [29] Safety, tolerability, and pharmacokinetics of oral baicalein tablets in healthy Chinese subjects: A single-center, randomized, double-blind, placebo-controlled multiple-ascending-dose study
    Li, Lijun
    Gao, Hongzhi
    Lou, Kun
    Luo, Hongmei
    Hao, Sheng
    Yuan, Jing
    Liu, Zeyuan
    Dong, Ruihua
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2021, 14 (05): : 2017 - 2024
  • [30] Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SPH3127: A Phase I, Randomized, Double-Blind, Placebo-Controlled Trial
    Jing, Shan
    Xu, Ranchi
    Yang, Kexu
    Liu, Wenfang
    Zhang, Leduo
    Ke, Ying
    Xia, Guangxin
    Lin, Yang
    CLINICAL THERAPEUTICS, 2021, 43 (04) : 735 - +
12345